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ttp://dx.doi.org/10.1016/j.ajpath.2014.02.023STAT4, which is activated mainly by IL-12, promotes inﬂammatory responses by inducing Th1 and Th2
cytokines. Recent genome-wide association studies indicate that STAT4 gene variants are associated with
risk of various types of liver diseases, but how STAT4 contributes to liver disease pathogenesis remains
obscure. In this study, STAT4 activation was detected in liver immune cells from patients with viral
hepatitis and autoimmune hepatitis, as well as in a mouse model of concanavalin A (Con A)einduced
hepatitis. Such STAT4 activation was detected mainly in T cells, natural killer T cells, and macrophages and
Kupffer cells, and was diminished in Il12a/ and Il12b/ mice. As expected, disruption of the Stat4
gene reduced production of Th1 and Th2 cytokines, but surprisingly exacerbated Con Aeinduced liver
injury. Similarly, disruption of Il12a or Il12b also augmented Con Aeinduced hepatocellular damage.
Further studies showed that hepatic natural killer T (NKT) cells from Con Aetreated Stat4/ mice
had higher levels of FasL expression and increased cytotoxicity against hepatocytes than those from Con
Aetreated WT mice. In vitro, blocking FasL attenuated Stat4/ NKT cytotoxicity against hepatocytes. In
conclusion, despite up-regulation of proinﬂammatory cytokines, STAT4 protects against acute T-cell
hepatitis, which is mediated by direct or indirect down-regulation of FasL expression on NKT cells.
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esis of a variety of liver diseases, including viral hepatitis,
autoimmune hepatitis (AIH), alcoholic hepatitis, non-
alcoholic steatohepatitis, and drug-induced liver injury.1e4
However, the molecular and cellular mechanisms underly-
ing immune-induced hepatocellular damage are not fully
understood.5 Over the last two decades, genome-wide asso-
ciation studies have identiﬁed that genetic variants of several
inﬂammation-related genes are associated with the risk of
various types of liver diseases, ﬁndings that not only enhance
our understanding of liver disease pathogenesis, but also
provide novel therapeutic targets for the treatment of liver
diseases.6e8 For example, several recent genome-wide as-
sociation studies have demonstrated that signal transducer
and activator of transcription 4 (STAT4) gene variants are
closely associated with the increased risk of hepatitis
Berelated liver cancer,9 primary biliary cirrhosis,10,11 and
hepatitis Ceinduced ﬁbrosis.12 However, how these STAT4
variants affect STAT4 gene expression and how STAT4 af-
fects liver injury and inﬂammation remain largely unknown.ogy.STAT proteins are a group of transcription factors that
transmit signals from the extracellular milieu of cells to the
nucleus. The seven known mammalian STAT family
members are STATs 1, 2, 3, 4, 5A, 5B, and 6. In the liver,
the functions of STATs 1, 3, and 6 have been extensively
investigated in many models of liver diseases,13 including
concanavalin A (Con A)einduced T-cell hepatitis. Injection
of mice with a single dose of Con A rapidly activates T cells
and natural killer T (NKT) cells and subsequently causes
hepatitis and liver injury, closely resembling the pathogen-
esis of AIH and viral hepatitis.1 With this model, we and
others have demonstrated that interferon g (IFN-g) and IL-4
play a critical role in promoting hepatocellular damage via
activation of STAT114 and STAT6,15 respectively, whereas
Wang et alIL-6 and IL-22 are important hepatoprotective cytokines
that protect against liver injury via activation of STAT3.14,16
In contrast to the well-documented hepatic functions of
STATs 1, 3, and 6, the roles of STAT4 in liver injury and
inﬂammation have not been carefully examined.
STAT4, which is activated mainly by IL-12,17e19 and to a
lesser extent by IFN-a/b,17 IL-2,18 and IL-17,20 plays critical
roles in regulating inﬂammatory responses in various types of
diseases.21 IL-12 is a heterodimeric 70-kDa glycoprotein
consisting of a 40-kDa subunit (encoded by human Il12b or
mouse Il12b) and a 35-kDa subunit (encoded by Il12a or
Il12a). On binding to an IL-12 receptor complex consisting
of IL-12R1 and IL-12R2, IL-12 predominantly activates
STAT4, and also weakly activates STAT1 and STAT3. IL-12
plays an important role in promoting inﬂammation and anti-
tumor immunity by inducing Th1 differentiation and IFN-g
production.19 The proinﬂammatory and antitumor effects of
IL-12 have also been documented in several animal models of
liver injury.22e25However, reports on the functions of STAT4
in liver injury and inﬂammation have been controversial. Shen
et al26 found that STAT4 knockout (KO) mice were resistant
to liver ischemiaereperfusion injury, but later Kato et al27
found that STAT4 KO mice and wild-type (WT) mice had
equal liver injury after ischemiaereperfusion. The reason for
the discrepancy between these two studies remains obscure.
In the present study, STAT4 activation was examined in
liver samples from patients with chronic viral hepatitis and
AIH, as well in a mouse model of Con Aeinduced T-cell
hepatitis. The role of IL-12 and STAT4 in the pathogenesis of
T-cell hepatitis was further investigated in Stat4/, Il12a/,
and Il12b/mice. Our ﬁndings reveal that STAT4 promotes
production of Th1 and Th2 cytokines, but inhibits expression
of FasL in NKT cells. STAT4 thus plays a dual role in con-
trolling T-cell hepatitis.
Materials and Methods
Materials
Anti-STAT4 and antiep-STAT4 (Tyr693) antibodies were
obtained from Cell Signaling Technology (Danvers, MA).
Neutralizing FasL antibody (clone MFL3) was obtained
from BD Biosciences (San Jose, CA). The sources of other
antibodies were as indicated below.
Liver Tissue Samples from Human Subjects
Cirrhotic liver samples (stage 3 to 4 ﬁbrosis) were collected
from donor livers during liver transplantation from the Liver
Tissue Cell Distribution System, University of Minnesota
(Minneapolis, MN).
Mice
Male WT BALB/c mice, Stat4 KO (Stat4/) mice on a
BALB/c background, WT C57BL/6J mice, Il12b KO1786(Il12b/) mice, and Il12a KO (Il12a/) mice on a
C57BL/6J background were obtained from the Jackson
Laboratory (Bar Harbor, ME). Colonies were maintained
and bred in the NIH National Institute on Alcohol Abuse
and Alcoholism (NIAAA) animal facility. Mice used in
experiments were 8 to 12 weeks of age. Handling of mice
and experimental procedures were in accordance with
institutional guidelines, and all animal experiments were
approved by the Institutional Animal Care and Use Com-
mittee of the NIAAA.
Induction of Mouse Hepatitis Model Induced by Con A
Con A (Sigma-Aldrich, St. Louis, MO) was dissolved in
PBS and injected intravenously through the tail vein at a
dose of 15 mg/kg for BALB/c mice and 12 mg/kg for
C57BL/6J mice. Serum from individual mice was obtained
at 0, 1, 2, 3, 6, 9, and 24 hours after Con A injection. Serum
alanine aminotransferase (ALT) activities were determined
using an IDEXX chemistry analyzer system (IDEXX Lab-
oratories, Westbrook, ME).
Immunohistochemistry
Liver sections from both human and mouse samples were
immunostained for p-STAT4 using an antiep-STAT4
antibody (Cell Signaling Technology). The number of
p-STAT4þ cells in the liver sections was counted in 10
randomly selected ﬁelds (200), and the average of the 10
ﬁelds was calculated.
Isolation and Culture of Primary Mouse Hepatocytes
Mice weighing 20 to 25 g were anesthetized intraperito-
neally with 30 mg/kg pentobarbital sodium, and the portal
vein was cannulated under aseptic conditions. The liver
was subsequently perfused with an EGTA solution [5.4
KCl, 0.44 KH2PO4, 140 NaCl, 0.34 Na2HPO4, 0.5 EGTA,
and 25 tricine (pH 7.2), all in mmol/L] and Dulbecco’s
modiﬁed Eagle’s medium (Life Technologies, Carlsbad,
CA) and digested with 0.075% collagenase solution. Iso-
lated mouse hepatocytes (5  104 per well) were then
cultured in Dulbecco’s modiﬁed Eagle’s medium contain-
ing 10% fetal calf serum and 2 mmol/L penicilline
streptomycin on rat-tail collagen-coated plates for 2 hours,
then in serum-free Dulbecco’s modiﬁed Eagle’s medium.
The hepatocytes were used to assay for NKT cytotoxicity
or Jo2 cytotoxicity.
Isolation of Hepatic Mononuclear Cells
The isolation of hepatic mononuclear cells (MNCs) was
performed as described previously.28 In brief, mouse livers
were removed and pressed through a 70-mm cell strainer.
The liver cells were suspended in PBS and centrifuged at
50  g for 5 minutes. Supernatants containing MNCs wereajp.amjpathol.org - The American Journal of Pathology
Figure 1 Activation of STAT4 in human liver diseases and inmouse T-cell hepatitis.A: Representative images of liver sections fromnormal healthy control subjects
and from patients with HBV, HCV, and AIH. Sections were immunostained with an antiep-STAT4 antibody. B: p-STAT4þ cells were counted in 10 randomly selected
high-power ﬁelds. C: Representative images of liver sections from Con Aetreated mice. Sections were immunostained with an antiep-STAT4 antibody; brown
indicates positive staining. D: p-STAT4þ cells were counted in 10 randomly selected high-power ﬁelds at various time points from baseline to 72 hours after Con A
injection. Data are expressed as means  SEM. nZ 3 to 10 patients per group (B). **P < 0.01; ***P < 0.001. Original magniﬁcation, 400.
STAT4 Attenuates T-Cell Hepatitiscollected, washed in PBS, and resuspended in 40% Percoll
medium (GE Healthcare, Little Chalfont, UK). The cell
suspension was gently overlaid onto 70% Percoll and was
centrifuged for 30 minutes at 750  g. MNCs were
collected from the interphase, washed twice in PBS, and
resuspended in PBS for ﬂuorescence-activated cell sorting
analysis or cytotoxicity assays.
Flow Cytometry Analysis
Single-cell suspension of liver or spleenMNCswaswashed in
PBS containing 1% bovine serum albumin. The cells were
surface-stained with ﬂuorochrome-conjugated monoclonal
antibody for 30minutes on ice. The antibodies usedwere anti-
CD3, anti-NK1.1, antieGr-1, anti-CD11b, anti-FasL, and
anti-CD69 (eBioscience, SanDiego, CA). CD1d tetramer was
obtained from the NIH Tetramer Core Facility at Emory
University (Atlanta, GA). For p-STAT4 staining, cells withThe American Journal of Pathology - ajp.amjpathol.orgsurface stainingwereﬁxed and permeabilized according to the
manufacturer’s instructions and then were incubated with p-
STAT4 antibody (BDBiosciences) at room temperature for 30
minutes. Samples were acquired on a FACSCalibur ﬂow cy-
tometer (BD Biosciences) and the data were analyzed using
FlowJo software version 7.6.5 (TreeStar, Ashland, OR).
Western Blotting
Tissues were homogenized in lysis buffer (30 mmol/L Tris at
pH 7.5, 150 mmol/L sodium chloride, 1 mmol/L ﬂuoride, 1
mmol/L sodium orthovanadate, 1% Nonidet P-40, 10% glyc-
erol) at 4C, vortexed, and centrifuged at 15,700 g at 4C for
10 minutes. The supernatants were mixed in Laemmli loading
buffer, boiled for 10minutes, and then subjected toSDS-PAGE.
After electrophoresis on 4% to 12% BiseTris gel (Life Tech-
nologies), proteins were transferred onto nitrocellulose mem-
branes and blotted against primary antibody overnight under1787
Figure 2 STAT4 is activated in multiple types of liver immune cells from
Con Aetreated mice, including T cells, NKT cells, and macrophages; the effect
is diminished in Il12a/ and Il12b/mice. A:Mice were injected with Con A
and liver lymphocytes were isolated at 9 hours after Con A administration.
Expression of p-STAT4 and surface expression of CD3þCD1d tetramerþ NKT
cells, NK1.1þCD3þ NKT cells, CD3þCD1d tetramer T cells, NK1.1CD3þ T cells,
CD11bþGr-1low macrophages, CD3B220þ B cells, and CD11bþGr-1high neu-
trophils were analyzed by ﬂow cytometry. Data are representative of three
independent experiments. B: WT, Il12b/, and Il12a/ mice were injected
with 12 mg/g Con A. At 9 hours after injection, liver tissues were collected for
p-STAT4 staining. p-STAT4þ cells were counted in 10 randomly selected ﬁelds
(200). Data are expressed asmeans of the 10 ﬁelds. ***P< 0.001. IL-12A-/-,
Il12a/; IL-12B-/-, Il12b/; SSC, side scatter.
Wang et alshaking conditions.Membranes were washedwith 0.05% (v/v)
Tween 20 in PBS (pH 7.4) and incubatedwith a 1:5000 dilution
of horseradish peroxidaseeconjugated secondary antibody for
1 hour. Protein bands were visualized by enhanced chem-
iluminescence reaction (Thermo Scientiﬁc, Waltham, MA).
H&E Staining of Liver Sections
After ﬁxation with 10% formalinePBS, livers were
parafﬁn-embedded, sliced, and stained with H&E.
TUNEL Staining
TUNEL-positive cells in sections of mouse livers were
detected using an in situ apoptosis detection kit (Millipore,
Billerica, MA) according to the manufacturer’s instructions.
Cytokine Measurement
Serum cytokine levels were measured using a cytometry bead
array (BD Biosciences) according to the manufacturer’s
protocol. The analysis was performed using a conventional
ﬂow cytometer (FACSCalibur; BD Biosciences).
Cytotoxicity Assay
For Jo2einduced cytotoxicity, hepatocytes were cultured in
serum-free Dulbecco’s modiﬁed Eagle’s medium and incu-
bated with different concentration of Jo2 antibody. For
hepatic MNC-induced cytotoxicity, hepatocytes were co-
cultured with hepatic MNCs isolated from Con Aetreated
mice for 4 hours with or without 10 mg/mL FasL neutralizing
antibody. Hepatocyte death was quantiﬁed by measuring
the activity of released aspartate transaminase (AST) in
culture medium. The speciﬁc cytotoxicity was calculated
as [(ASTexperimental  ASTspontaneous)/(ASTmaximum 
ASTspontaneous)]  100.
Statistical Analysis
Student’s two-sample t-test was performed to compare
values from two groups. To compare values from three or
more groups, one-factor analysis of variance was used,
followed by Tukey’s post hoc test. P values of <0.05 were
considered signiﬁcant.
Results
STAT4 Is Activated in Inﬂammatory Cells in Livers from
Patients with Chronic Liver Diseases and in a Mouse
Model of T-Cell Hepatitis
To investigate the roles of STAT4 in the pathogeneses of liver
diseases, we ﬁrst performed immunohistochemistry analyses
of phosphorylated STAT4 (p-STAT4) in liver sections from
patients with viral hepatitis B (HBV), viral hepatitis C (HCV),
or AIH. Very few p-STAT4þ cells were detected in normal1788healthy control livers, but strong p-STAT4 staining was
found in inﬂammatory cells from livers of HBV, HCV, and
AIH patients (Figure 1A). p-STAT4 staining was not
observed in hepatocytes. The total number of p-STAT4þ cells
was signiﬁcantly higher in livers from patients with HBV,
HCV, and AIH than in healthy control livers (Figure 1B).
Next, we performed immunohistochemistry analyses of
p-STAT4 in a mouse model of inﬂammatory liver injury
induced by Con A administration. p-STAT4þ cells were not
observed in the livers from mice without Con A treatment
(Figure 1C). After Con A injection, p-STAT4þ cells were
detected in the livers, with peak effects occurring 9 hours
after injection, and disappeared 48 and 72 hours after Con A
injection. In agreement with the immunostaining ﬁndings
from human samples, p-STAT4 was detected in inﬂamma-
tory cells but not in hepatocytes.
STAT4 Is Activated in Multiple Types of Liver
Inﬂammatory Cells from Con AeTreated Mice,
Including T Cells, NKT Cells, and Macrophages, but the
Activation Is Diminished in Il12a/ and Il12b/
Mice
To further deﬁne the p-STAT4þ cell types in the liver and
spleen, ﬂow cytometric analyses were used to analyze MNCsajp.amjpathol.org - The American Journal of Pathology
STAT4 Attenuates T-Cell Hepatitisisolated from mice at 9 hours after Con A treatment or saline
treatment. We chose the 9-hour time point because peak
levels of p-STAT4 activation occurred at this time (Figure 1).
Mice without Con A treatment had very few p-STAT4þ
MNCs in the liver; however, approximately 1% to 2% of he-
patic MNCs from Con Aetreated mice were p-STAT4þ
(Figure 2A). Of these p-STAT4þ cells, approximately 9%were
NKT cells (CD1d tetramerþCD3þ), 12% were NK cells
(NK1.1þCD3), and 30% were T cells (NK1.1CD3þ).
Approximately 26% of the p-STAT4þ cells were CD11bþGr-
1low cells (macrophages and Kupffer cells), and 5% were
CD11bþGr1high cells (neutrophils). These ﬁndings suggest that
STAT4 is activated in multiple types of liver immune cells
from Con Aetreated mice. Similarly, STAT4 was also acti-
vated in multiple immune cells (eg, T cells and NKT cells) in
the spleen after Con A injection (Supplemental Figure S1A).
STAT4 is activated mainly by IL-12, and to a lesser extent
by IFN-a/b, IL-12, and IL-17.17e20,29e32 To test whether
IL-12 is a major factor responsible for activation of STAT4 in
the liver after administration of Con A, we used WT and
Il12a/or Il12b/mice. Liver tissues were collected for p-
STAT4 immunohistochemistry staining. p-STAT4þ cells
were detected in livers of WT mice, but not of Il12a/ or
Il12b/ mice (Figure 2B and Supplemental Figure S1B).
These ﬁndings indicate that STAT4 activation in the Con
Aeinduced hepatitis model is IL-12 dependent.
Stat4/ Mice Have Lower Serum Levels of Cytokines
after Con A Injection than WT Mice
Given that STAT4 plays a critical role in the control of Th1 and
Th2 cytokine production,21 we hypothesized that cytokineFigure 3 Stat4/ mice have lower serum levels of cytokines after Con A injec
A, and serum cytokine levels were determined using cytometric bead array at var
means  SEM. n Z 4 or 5 mice. *P < 0.05, **P < 0.01, and ***P < 0.0001 ve
The American Journal of Pathology - ajp.amjpathol.orgproduction would be attenuated in Stat4/ mice, compared
with WT mice, in the Con Aemediated hepatitis model. As
expected, Con A injectioneinduced elevation of IFN-g, IL-4,
and IL-12 was signiﬁcantly attenuated in Stat4/ mice,
comparedwithWTmice (Figure 3). Elevationof serum IL-6 and
TNF-a was slightly (but signiﬁcantly) inhibited in Stat4/
mice, comparedwithWTmice, after ConA injection (Figure 3).
However, serum levels of IL-10,MCP-1, and IL-22were similar
in Con Aetreated WT and Stat4/ mice (data not shown).
Stat4/, Il12a/, and Il12b/ Mice Are More
Susceptible to Con AeInduced Murine Hepatitis than
WT Mice
Because IFN-g and IL-4 play critical roles in Con Ae
induced liver injury,14,15 we hypothesized that Stat4/
mice (which have reduced production of both cytokines)
would have reduced liver injury after Con A injection.
Surprisingly, however, Stat4/ mice had larger areas of
necrosis and higher levels of serum ALT than WT mice
after Con A injection (Figure 4, AeC).
Because STAT1 and STAT3 are known to play important
roles in regulating liver regeneration,13 we wondered whether
STAT4 also regulates liver regeneration. Western blot anal-
ysis revealed that hepatic activation of both p-STAT1 and
p-STAT3 was lower in Stat4/ mice than in WT mice
(Supplemental Figure S2C), which is in agreement with the
ﬁnding that Stat4/mice had lower levels of IFN-g and IL-6
after Con A injection, compared with WT mice (Figure 3).
Despite lower levels of hepatic STAT3 activation, Con
Aetreated Stat4/mice had greater numbers of hepatocytes
positive for bromodeoxyuridine (BrdUþ), compared withtion, compared with WT mice. WT and Stat4/mice were injected with Con
ious time points from 1 to 24 hours after injection. Data are expressed as
rsus corresponding Con Aetreated WT group. STAT4-/-, Stat4/.
1789
Figure 4 Stat4/, Il12a/, and Il12b/ mice are more susceptible to Con Aeinduced murine hepatitis. A and B: WT and Stat4/ mice were
injected with 15 mg/g Con A. H&E-stained sections were analyzed for necrosis (outlined areas) at baseline and at 9 and 24 hours after injection (A) and
Percentage necrotic area in Stat4/ and WT mice at 9 and 24 hours after Con A injection (B). C: Serum ALT levels in Stat4/ and WT mice were
determined at 0, 6, 9, and 24 hours. DeF: WT, Il12b/, and Il12a/ mice were injected with 12 mg/g Con A. D: Serum ALT activity was determined at
9 hours after injection. E and F: H&E-stained sections were analyzed for necrosis (outlined areas) (E) and the necrotic area was calculated as a
percentage (F). Representative images are shown. Data are expressed as means  SEM. n Z 4 to 12 mice. *P < 0.05, **P < 0.01, and ***P < 0.001.
Original magniﬁcation, 100.
Wang et alCon AetreatedWTmice (Supplemental Figure S2, B and C).
This ﬁnding suggests that the increased liver injury observed
in Stat4/mice was not due to impaired liver regeneration in
these mice.
Next, we investigated Con Aeinduced liver injury in
Il12a/ and Il12b/ mice; livers of these mice had very
few p-STAT4þ cells after Con A treatment (Figure 2B and1790Supplemental Figure S1B). Serum levels of ALT were
higher in Con Aetreated Il12a/ and Il12b/ mice,
compared with WT mice (Figure 4D). Liver histology an-
alyses also conﬁrmed that Il12a/ and Il12b/ mice had
larger areas of necrosis than WT mice after Con A injection
(Figure 4, E and F). These ﬁndings conﬁrm the protective
role of STAT4 in T-cell hepatitis.ajp.amjpathol.org - The American Journal of Pathology
Figure 5 FasL levels are higher in NKT cells from Stat4/ mice than
from WT mice after Con A injection. A and B: Hepatic MNCs isolated from
Con Aeinjected WT and Stat4/ mice were subjected to real-time quan-
titative PCR analyses (A) and ﬂow cytometric analyses of CD69 and FasL in T
cells and NKT cells (B). Representative ﬂow cytometric graphs from 3 hours
Con Aetreated mice are shown. Fold-change data are expressed as means 
SEM. *P < 0.05; **P < 0.01.
STAT4 Attenuates T-Cell HepatitisNKT Cells from Stat4/ Mice Have Higher Levels of
FasL and Greater Cytotoxicity against Hepatocytes
than Those from WT Mice
Our ﬁnding that Stat4/ mice have reduced cytokine pro-
duction after Con A injection, compared with WT mice,
cannot explain the exacerbated liver injury in Stat4/The American Journal of Pathology - ajp.amjpathol.orgmice. Because NKT cell killing of hepatocytes plays an
important role in promoting Con Aeinduced hepatitis,33
we measured mRNA levels of cytotoxicity-associated
genes (eg, perforin, granzyme B, and FasL) in WT and
Stat4/ mice after Con A injection. No signiﬁcant dif-
ference was found in the expression levels of perforin and
granzyme B (data not shown). However, expression
levels of hepatic FasL mRNA were signiﬁcantly higher in
Stat4/ mice after Con A administration, compared with
WT mice (Figure 5A).
Next, we performed ﬂow cytometric analyses to deter-
mine which cell types express FasL. Consistent with pre-
vious report,33 Con A injection increased expression of
FasL in NKT cells but not in T cells, and expression of the
activation marker CD69 was up-regulated in both T cells
and NKT cells (Figure 5B). Expression of CD69 was similar
in WT and Stat4/ mice after Con A injection, whereas
expression of FasL protein was higher in NKT cells from
Con Aetreated Stat4/ mice, compared with WT mice
(Figure 5B).
TUNEL analyses revealed that, after Con A injection,
Stat4/ mouse livers had greater numbers of TUNELþ
hepatocytes than did WT mouse livers (Figure 6, A and B),
suggesting that Con A injection induces more hepatocyte
apoptosis in Stat4/ mice than in WT mice.
Although there was no indication that STAT4 was acti-
vated in hepatocytes, we could not rule out the possibility
that Stat4/ hepatocytes are more sensitive to FasL-induced
cell death than are WT hepatocytes. To address this question,
we isolated hepatocytes from WT and Stat4/ mice and
incubated the cells with 5 mg/mL or 10 mg/mL anti-Fas anti-
body Jo2 for 4 hours to mimic FasL-induced hepatocyte
apoptosis, and then determined the cytotoxicity. We found no
difference between the sensitivity of WT hepatocytes and
Stat4/ hepatocytes to Jo2-induced cell death (Figure 6C).Figure 6 Increased cytotoxicity against hepa-
tocytes of NKT cells from Stat4/ mice after Con A
injection, relative to NKT cells from WT mice. A: WT
and Stat4/ mice were treated with Con A; at 9
hours after injection, liver tissues were subjected
to TUNEL immunostaining. Arrows indicate
TUNELþ hepatocytes. B: TUNELþ hepatocyte per-
centage. C: Hepatocytes were isolated from WT and
Stat4/ mice and treated with Jo2 anti-Fas
antibody; cell death was then determined. D: WT
mouse hepatocytes were incubated with hepatic
MNCs that were isolated from 2-hour Con Ae
treated WT mice, with or without neutralizing FasL
monoclonal antibody MFL3; cytotoxicity was then
determined. Data are expressed as means  SEM.
**P < 0.01; ***P < 0.001. E/T, effector (MNCs)/
target (hepatocytes); Hep, hepatocytes.
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Wang et alWe also wanted to determine whether Stat4/ NKT
cells have greater cytotoxicity against hepatocytes than do
WT NKT cells. Because NKT cells are the major cell type
responsible for liver MNC-mediated cytotoxicity against
hepatocytes, we used MNCs as a proxy for NKT cell
cytotoxicity. In addition, a marked depletion of liver NKT
cells was observed 4 to 20 hours after intravenous in-
jection of Con A into WT mice.33 We therefore isolated
liver MNCs at an early time point (2 hours) after Con A
injection. MNCs isolated from Con Aetreated Stat4/
mice exhibited enhanced cytotoxicity against hepatocytes,
compared with WT mice (Figure 6D). The enhanced
cytotoxicity in the Stat4/ MNC group was remarkably
reduced when a FasL neutralizing monoclonal antibody
was added.Figure 7 A complex role of IL-12 and STAT4 in pathogenesis of Con
Aeinduced liver injury. Con A activates T cells and NKT cells to produce a
variety of cytokines (eg, IFN, IL-2, and IL-17), and these cytokines stimulate
immune cells (eg, monocytes, macrophages, and dendritic cells) to produce
IL-12. In a positive feedback loop, IL-12 stimulates its own production via
activation of STAT4. IL-12 also activates STAT4 in NKT cells and in macro-
phages and Kupffer cells to produce IFN-g, IL-4, and TNF-a, thereby exac-
erbating Con Aeinduced hepatitis. By contrast, activation of STAT4 by IL-12
indirectly or directly down-regulates FasL in NKT cells and protects against
Con Aeinduced hepatitis. STAT4-mediated down-regulation of FasL may
dominate over STAT4-mediated up-regulation of proinﬂammatory cytokines
in the Con Aeinduced T-cell hepatitis model, leading to the observed pro-
tection of STAT4 against liver injury in this model.Discussion
With the present study, we have demonstrated that STAT4
is activated by IL-12 in T cells, NKT cells, and macro-
phages and Kupffer cells in Con Aeinduced T-cell hepa-
titis. We have also demonstrated that disruption of the
STAT4 gene reduces the production of Th1 and Th2 cy-
tokines but, surprisingly, exacerbates hepatocellular dam-
age, suggesting that IL-12 activation of STAT4 in T cells,
NKT cells, and macrophages plays a role in ameliorating
Con Aeinduced liver injury. Further studies suggest that
the protective effect of STAT4 is mediated by down-
regulating the expression of FasL in NKT cells. We have
integrated all of these ﬁndings into a model (Figure 7)
describing the complex role of STAT4 in control of Con
Aeinduced hepatitis by regulating the balance of inhibition
of Fas/FasL-mediated hepatotoxicity and by up-regulating
proinﬂammatory cytokines.
IL-12 Is Essential for STAT4 Activation in Inﬂammatory
Cells, and STAT4 Partially Contributes to IL-12
Production in Con AeInduced Hepatitis
STAT4 is activated mainly by IL-1217e19 and to a much
lesser degree by IFN-a/b,17 IL-2,18 and IL-17.20 Serum levels
of IL-12 elevation (Figure 3) correlated well with p-STAT4
activation in liver MNCs (Figure 1), with both peak effects
occurring 9 hours after Con A injection. Furthermore,
disruption of the Il12a or Il12b gene completely abolished
STAT4 activation in Con Aeinduced hepatitis (Figure 2 and
Supplemental Figure S1B), suggesting that IL-12 plays an
essential role in inducing STAT4 activation in this model. IL-
12 is produced mainly by monocytes, macrophages, and
dendritic cells.34 Injection of Con Aeinduced elevation of
IL-12p70, with one peak at 3 hours after injection and another
at 9 hours. Disruption of the Stat4 gene markedly prevented
elevation of IL-12p70 at 3 hours after Con A injection and
also, to a lesser extent, at 9 hours after injection. These
ﬁndings indicate that STAT4 contributes partially to1792IL-12p70 production, with amore important role at early time
points (eg, 3 hours) and a less important role at later time
points (eg, 9 hours) after Con A injection. Taken together, our
ﬁndings suggest that IL-12 acts in a positive feedback loop to
induce its own production via activation of STAT4 in
immune cells such as monocytes, macrophages, and dendritic
cells. In addition to STAT4, other signaling pathways acti-
vated by IFN-a/b,17 IL-2,18 and IL-1720 likely also contribute
to IL-12 production.
IL-12 Activation of STAT4 Plays a Protective Role in
Con AeInduced Hepatitis via Inhibition of FasL
Expression in NKT Cells
IL-12 activation of STAT4 plays an important role in pro-
moting Th1 (IFN-g) and Th2 (IL-4) cytokine production.19
In accord with this notion, serum levels of IFN-g, IL-4, and
TNF-a were lower in Stat4/ mice than in WT mice
(Figure 3). All of these cytokines have been shown to exac-
erbate Con Aeinduced T-cell hepatitis.1 Surprisingly, how-
ever, Con Aeinduced liver injury was markedly enhanced in
Stat4/ mice, relative to WT mice (Figure 4). Similarly,
disruption of the Il12a or Il12b gene also exacerbated Conajp.amjpathol.org - The American Journal of Pathology
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(Figure 4). Interestingly, our present ﬁndings are in contrast
to earlier reports on the role of IL-12 in Con Aeinduced liver
injury. In an early study, treatment of mice with IL-12
exacerbated Con Aeinduced liver injury, and blocking IL-
12 with a neutralizing antibody reduced the injury; howev-
er, Con Aeinduced liver injury was similar in WT and
Il12b/ mice.35 In a later study, Il12b/ mice were less
susceptible to Con Aeinduced T-cell hepatitis than were WT
mice.24 The discrepancies among these studies and our pre-
sent study may be explained by differences in the doses used
(20 mg/g Con A in the two previous studies versus 12 mg/g in
the present study) and to the dual roles of IL-12 and STAT4
in controlling Con Aeinduced hepatitis (discussed below).
In contrast to the reduced serum cytokine levels, FasL
expression in NKT cells from Con Aetreated Stat4/ mice
was signiﬁcantly higher than that from Con Aetreated WT
mice (Figure 5). It is not clear whether the elevated FasL
expression in NKT cells from Stat4/ mice was due to a
compensatory mechanism in KO mice, nor whether STAT4
directly or indirectly down-regulates FasL expression in
NKT cells. IL-4 treatment has been reported to up-regulate
expression of FasL in NKT cells.36 Our present ﬁndings,
that IL-4 levels were lower but FasL levels were higher in
Con Aetreated Stat4/ mice than in WT mice, suggest that
STAT4-mediated down-regulation of FasL expression on
NKT cells is not mediated by the stimulation of IL-4.
Further studies are required to identify the mechanisms for
reduced FasL expression in NKT cells of Stat4/ mice,
compared with WT mice.
The next question is whether up-regulation of FasL
expression in NKT cells contributes to the enhanced liver
injury in Con Aetreated Stat4/mice. In one study, caspase
inhibition did not prevent Con Aeinduced liver injury, sug-
gesting that Con A treatment induces a caspase-independent
necrotic death.37 Several other studies, however, suggest
that FasL-mediated apoptosis contributes to Con Aeinduced
liver injury. First, FasL- and Fas-deﬁcientmice are resistant to
ConAeinduced liver injury.36,38,39 Second, administration of
a FasL-neutralizing monoclonal antibody reduces Con
Aeinduced T-cell hepatitis.38 Third, although Con
Aeinduced liver injury is associated predominantly with
necrosis,39,40 signiﬁcant hepatocyte apoptosis was detected in
the liver after Con A injection (Figure 6A). These ﬁndings
suggest that both apoptosis and necrosis contribute to Con
Aeinduced hepatocyte damage. However, how apoptotic
injury elicited by FasL translates into necrosis in this model is
not clear. In the present study, up-regulation of FasL
expression was detected as early as 3 hours after Con A in-
jection, with higher levels in Stat4/ mice than in WT mice
(Figure 5). This upregulation may contribute to the higher
levels of ALT elevation in Stat4/ mice at early time points
(eg, 6 hours) after Con A injection, compared with WT mice
(Figure 4).
In addition to elevated FasL, which induces hepatocyte
apoptosis, other factors may also contribute to the increasedThe American Journal of Pathology - ajp.amjpathol.orgsusceptibility of Stat4/ mice to Con Aeinduced liver
injury, because necrosis also signiﬁcantly contributes to Con
Aeinduced hepatocellular damage.37 In the present study,
Stat4/ mice had greater necrosis than WT mice after Con
A injection. Given the well-documented hepatoprotective
function of IL-6 in ameliorating Con Aeinduced necrosis,14
lower levels of IL-6 in Con Aetreated Stat4/ mice likely
also contribute to the higher levels of liver injury in these
mice, compared with WT mice.
In summary, given the complex pathogenesis of Con
Aeinduced T-cell hepatitis, which is controlled both by
interaction among T cells, NKT cells, and macrophages and
Kupffer cells and by interaction between pro- and anti-
inﬂammatory cytokines,1 STAT4 likely plays a multifaceted
role in controlling T-cell hepatitis by targeting several types
of immune cells and regulating expression of various cy-
tokines, including IL-12 (Figure 7).
STAT4 Activation in Liver Diseases
STAT4 gene variants have been implicated in pathogenesis
of various types of liver diseases.9e12 However, how these
variants affect STAT4 expression or activation and how
STAT4 contributes to liver injury and inﬂammation remain
largely unknown. In the present study, immunohistochem-
istry analyses revealed strong STAT4 activation in inﬂam-
matory cells (but not in hepatocytes) in the liver tissues from
patients with chronic HBV, HCV, and AIH, conditions in
which T cellemediated immune responses play a central
role in hepatocellular injury. Thus, activation of STAT4 in
viral hepatitis and AIH likely promotes production of Th1
and Th2 cytokines and subsequently exacerbates liver
inﬂammation and injury; however, such activation may also
down-regulate FasL expression in NKT cells, thereby
reducing hepatocellular damage. The net effect of STAT4
activation on the progression of liver injury is determined by
the balance between inhibition of FasL expression and up-
regulation of proinﬂammatory cytokines. Further studies
are needed to clarify the multiple functions of STAT4 in the
liver and to translate these ﬁndings into clinical practice and
therapy.
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